Ä¢¹½ÊÓƵAPP

Jeff DeVito joined Ä¢¹½ÊÓƵAPP in 2022 as Senior Director, Program Management for Pioneering Medicines. He is currently responsible for managing a complex collaboration, integrating innovative technologies in pursuit of curative therapy for a specific subset of patients with a rare disease.

Jeff has over 20 years of industry experience in both discovery research and clinical development. Starting his career as an in vivo pharmacologist at Aventis (and then Sanofi), Jeff was the lead biologist on a number of multidisciplinary research teams. Ten years ago, Jeff transitioned to a drug development program management position at Celgene where he played critical roles in bringing Revlimid to the worldwide market, the IND and Phase 1 trial for an immunomodulatory drug, and FDA approval of Inrebic, the first new myelofibrosis therapy in almost a decade. Most recently, Jeff was the Head of Hematology Project Management at Bristol Myers Squibb.

Jeff received a B.S. in Biology from The College of New Jersey and an M.S. in Cell and Developmental Biology from UMDNJ-Rutgers University.